최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Phytomedicine : international journal of phytotherapy and phytopharmacology, v.77, 2020년, pp.153270 -
Zhao, Qing (Corresponding author.) , Wei, Mengjuan , Zhang, Shaobo , Huang, Zhenlin , Lu, Bin , Ji, Lili
Abstract Background Sophorae tonkinensis Radix et Rhizoma is traditionally used for clearing away heat and toxic materials in China. Purpose This study aims to observe the amelioration of Sophorae tonkinensis water extract (STR) against non-alcoholic fatty liver disease (NAFLD) and the engaged m...
Liver Int. Suppl. Araujo 1 47 2018 10.1111/liv.13643 Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future
Dig. Dis. Sci. Arrese 61 1294 2016 10.1007/s10620-016-4049-x Innate immunity and inflammation in NAFLD/NASH
Hepatology Bedossa 60 565 2014 10.1002/hep.27173 Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Hum. Pathol. Brunt 35 1070 2004 10.1016/j.humpath.2004.04.017 Nonalcoholic steatohepatitis : histologic features and clinical correlations with 30 blinded biopsy specimens
Metabolism Buzzetti 65 1038 2016 10.1016/j.metabol.2015.12.012 The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
J. Hepatol. Byrne 62 1 Suppl S47 2015 10.1016/j.jhep.2014.12.012 NAFLD : a multisystem disease
Nutrients Chen 9 E96 2017 10.3390/nu9020096 Effects of natural products on fructose-induced nonalcoholic fatty liver disease (NAFLD)
Zhongguo Zhong Yao Za Zhi Chen 42 2439 2017 Pharmacological effect and toxicology of Sophorae Tonkinensis Radix et Rhizoma
27 2015 Pharmacopeia of Thepeople's Republic of China (2015) Version
J. Clin. Exp. Hepatol. Choudhary 9 731 2019 10.1016/j.jceh.2019.06.004 Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease
Gastroenterology Dela Pena 129 1663 2005 10.1053/j.gastro.2005.09.004 NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis
Diabetes Dibba 6 83 2018 Emerging therapeutic targets and experimental drugs for the treatement of NAFLD
J. Transl. Med. Gao 16 319 2018 10.1186/s12967-018-1685-2 Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway
Cell Death. Dis. George 10 18 2019 10.1038/s41419-018-1272-8 Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis
Hepatol. Int. Golabi 13 688 2019 10.1007/s12072-019-09995-8 Hepatocellular carcinoma and non-alcoholic fatty liver disease
Annu. Rev. Physiol. Houten 78 23 2016 10.1146/annurev-physiol-021115-105045 The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders
Dig. Dis. Sci. Ibrahim 61 1325 2016 10.1007/s10620-015-3977-1 Animal models of nonalcoholic steatohepatitis : eat, delete, and inflame
Int. J. Clin. Exp. Pathol. Itagaki 6 2683 2013 Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice
Hepatology Kleiner 41 1313 2005 10.1002/hep.20701 Design and validation of a histological scoring system for nonalcoholic fatty liver disease
Arch. Pharm. Res. Lee 42 935 2019 10.1007/s12272-019-01178-1 Molecular insights into the role of mitochodnria in non-alcoholic fatty liver disease
World J. Gastroenterol. Liu 23 1964 2017 10.3748/wjg.v23.i11.1964 Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease
Curr. Pharm. Des. Lonardo 19 5177 2013 10.2174/1381612811319290003 Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD
Cell Mol. Life Sci. Mandard 61 393 2004 10.1007/s00018-003-3216-3 Peroxisome proliferator-activated receptor alpha target genes
J. Hepatol. Mridha 66 1037 2017 10.1016/j.jhep.2017.01.022 NLRP3 inflammasome blockage reduces liver inflammation and fibrosis in experimental NASH in mice
J. Hepatol. Pawlak 62 720 2015 10.1016/j.jhep.2014.10.039 Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
PLoS ONE Rakhshandehroo 4 e6796 2009 10.1371/journal.pone.0006796 Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human
Lab. Anim. Ramadori 49 1 Suppl 47 2015 10.1177/0023677215570078 Mouse models of metabolic liver injury
Hepatol. Int. Reimer 14 8 2020 10.1007/s12072-019-10001-4 New drugs for NAFLD : lessons from basic models to the clinic
J. Lipid Res. Rinella 49 1068 2008 10.1194/jlr.M800042-JLR200 Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
Cell Metab. Samuel 27 22 2018 10.1016/j.cmet.2017.08.002 Nonalcoholic fatty liver disease are a nexus of metabolic and hepatic diseases
Eur. J. Pharmacol. Shi 714 89 2013 10.1016/j.ejphar.2013.06.013
J. Clin. Exp. Hepatol. Thiagarajan 9 515 2019 10.1016/j.jceh.2019.03.002 Drug development for nonalcoholic fatty liver disease : landscape and challenges
Ann. Neurosci. Vishwanath 23 51 2016 10.1159/000443556 Fatty Acid Beta-Oxidation Disorders: a Brief Review
Curr. Drug Targets Xu 16 1347 2015 10.2174/1389450116666150531155711 Natural products on nonalcoholic fatty liver disease
Front. Pharmacol. Zhang 9 1459 2018 10.3389/fphar.2018.01459 Herbal extracts and natural products in alleviating non-alcoholic fatty liver disease via activating autophagy
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.